Table 1.
Comparison of clinicopathological patient characteristics as well as TPX2 expression between the non-gemcitabine-based and the gemcitabine-based palliative treatment subgroups in the advanced PDAC cohorts.
Treatment arm, no (%) | |||
---|---|---|---|
Non-gemcitabine-based (n = 40) | Gemcitabine-based (n = 99) | P value (χ2) | |
Sex | |||
Female | 22 (55.0) | 57 (57.6) | 0.78 |
Male | 18 (45.0) | 42 (42.4) | |
Age (years) | |||
≤60 | 16 (40.0) | 41 (41.4) | 0.88 |
>60 | 24 (60.0) | 58 (58.6) | |
TPX2 expression | |||
Low | 36 (90.0) | 84 (84.8) | 0.42 |
High | 4 (10.0) | 15 (15.2) | |
KPS | |||
≤80 | 18 (45.0) | 33 (14.9) | 0.21 |
>80 | 22 (55.0) | 65 (85.1) | |
Grade group | |||
G1–G2 | 14 (37.5) | 47 (21.2) | 0.21 |
G3–G4 | 26 (62.5) | 52 (78.8) | |
Stage at therapy start | |||
Locally advanced | 7 (17.5) | 17 (17.2) | 0.96 |
Metastatic | 33 (82.5) | 82 (82.8) |